ENA20 Poster 207: Benchmarking Syngeneic Tumor Immunity through Immune Subset Depletion

Benchmarking Syngeneic Tumor Models to Explore Immuno-Pathogenesis by Depletion of a Series of Immune Lineages

Annie Xiaoyu An, Ying Jin, Ruilin Sun*, Binchen Mao, Davy Xuesong Ouyang, Henry Q. Li
*Shanghai Model Organisms Center

Syngeneic models respond differently to various checkpoint inhibitors, based on the unique intrinsic tumor immunity of each model, as well as specific mechanisms of action of each agent. Our knowledge of these mechanisms is limited, however, due to large experimental variation and a lack of comprehensive benchmarking of syngeneic model panels.

This poster presents the systematic benchmarking of a panel of syngeneic models, including MC38, Hepa 1-6, CT26.WT, and EMT6. The model intrinsic tumor immunity was assessed by depleting key immune subsets, with the associated pharmacodynamics of tumor-infiltrating leukocytes (TILs) also evaluated by flow cytometry.

Read this Poster to Discover:

• That syngeneic models clearly differ from each other, implicating distinctive intrinsic tumor immunity
  
  
• That CD8+ T cells are the major driver of antitumor activities for MC38 and EMT6 syngeneic models, while CD4+ T cells play a pivotal role in fighting tumors in the Hepa 1-6 model
  
  
• That genetically engineered mouse models expressing DTR for inducible conditional lineage depletion, can provide more clear cut results than depletion antibodies, suggesting a useful tool complementary to depletion antibodies, particularly in cases where there are no surface markers for a specific lineage (e.g. Treg cells)

Download the Poster Now!